HIGHLIGHTS
- who: Sanjay Kumar Mishra from the Department of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, Delhi, New Delhi, India have published the Article: Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients, in the Journal: (JOURNAL)
- what: The aim of this study was to compare the effectiveness and safety of two anti-VEGF drugs: brolucizumab and aflibercept in treatment-naïve nAMD Indian patients over a period of 48 weeks.
SUMMARY
Ranibizumab is FDA approved at a dosing interval . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.